Disease management programs for heart failure: Not just for the 'sick' heart failure population

被引:13
作者
McDonald, Ken [1 ]
Conlon, Carmel [1 ]
Ledwidge, Mark [1 ]
机构
[1] St Vincents Univ Hosp, Heart Failure Unit, Dublin 4, Ireland
关键词
D O I
10.1016/j.ejheart.2006.05.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of disease management programs has been a major advance in heart failure care, bringing about significant improvements for the heart failure population, with reduction in readmission, better use of guideline therapy and improved survival. However, at present, the majority of such programs focus their attention only on the sicker segment of this population, with little application of this important service to the broader heart failure population, where potentially benefits may be even more impressive. This has led to an imbalance in the care of patients with heart failure, where aspects of management such as regular structured review and education are preferentially given to the group at the later stages of the natural history of the syndrome. This paper argues for a far wider application of the disease management program concept in heart failure care so as to bring the benefits of specialist care, patient education and follow-up to patients at an earlier stage in the natural history of heart failure. (c) 2006 European Society of Cardiology. Published by Elsevier B.V All rights reserved.
引用
收藏
页码:113 / 117
页数:5
相关论文
共 31 条
[1]   Disease management: State of the art and future directions [J].
Armstrong, EP .
CLINICAL THERAPEUTICS, 1999, 21 (03) :593-609
[2]   Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [J].
Bardy, GH ;
Lee, KL ;
Mark, DB ;
Poole, JE ;
Packer, DL ;
Boineau, R ;
Domanski, M ;
Troutman, C ;
Anderson, J ;
Johnson, G ;
McNulty, SE ;
Clapp-Channing, N ;
Davidson-Ray, LD ;
Fraulo, ES ;
Fishbein, DP ;
Luceri, RM ;
Ip, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :225-237
[3]   Randomised controlled trial of specialist nurse intervention in heart failure [J].
Blue, L ;
Lang, E ;
McMurray, JJV ;
Davie, AP ;
McDonagh, TA ;
Murdoch, DR ;
Petrie, MC ;
Connolly, E ;
Norrie, J ;
Round, CE ;
Ford, I ;
Morrison, CE .
BRITISH MEDICAL JOURNAL, 2001, 323 (7315) :715-718
[4]   Cost/utility ratio in chronic heart failure: Comparison between heart failure management program delivered by day-hospital and usual care [J].
Capomolla, S ;
Febo, O ;
Ceresa, M ;
Caporotondi, A ;
Guazzotti, G ;
La Rovere, MT ;
Ferrari, M ;
Lenta, F ;
Baldin, S ;
Vaccarini, C ;
Gnemmi, M ;
Pinna, G ;
Maestri, R ;
Abelli, P ;
Verdirosi, S ;
Cobelli, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1259-1266
[5]   Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care [J].
Cowie, MR ;
Struthers, AD ;
Wood, DA ;
Coats, AJS ;
Thompson, SG ;
PooleWilson, PA ;
Sutton, GC .
LANCET, 1997, 350 (9088) :1349-1353
[6]   Care management for low-risk patients with heart failure - A randomized, controlled trial [J].
DeBusk, RF ;
Miller, NH ;
Parker, KM ;
Bandura, A ;
Kraemer, HC ;
Cher, DJ ;
West, JA ;
Fowler, MB ;
Greenwald, G .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (08) :606-613
[7]   Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure [J].
Feola, M ;
Aspromonte, N ;
Canali, C ;
Ceci, V ;
Giovinazzo, P ;
Milani, L ;
Quarta, G ;
Ricci, R ;
Scardovi, AB ;
Uslenghi, E ;
Valle, R .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (05) :705-709
[8]  
FREEMAN DA, 1998, DIS MANAG HEALTH OUT, V1, P111
[9]   Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction [J].
Heidenreich, PA ;
Gubens, MA ;
Fonarow, GC ;
Konstam, MA ;
Stevenson, LW ;
Shekelle, PG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (06) :1019-1026
[10]  
Hunt SA, 2005, CIRCULATION, V112, pE154, DOI [10.1161/CIRCULATIONAHA.105.167586, 10.1161/CIRCULATIONAHA.105.167587]